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Summary: A variety of movement disorders are known to 
occur in association with carbamazepine (CBZ) therapy 
in adults and children, but development of tics has been 
described infrequently and only in patients with underly- 
ing Tourette’s syndrome or other movement disorders. 
We report 3 children with epilepsy who developed facial 
motor tics after initiation of CBZ for complex partial sei- 
zures. All 3 had documented CBZ blood levels in the 
therapeutic range at the time, and none had other symp- 
toms or signs of clinical intoxication. Neurologic exami- 
nations were normal in 2 and showed developmental de- 
lay of expressive language in the third. Brain imaging was 
normal in all. After development of the tics in 2, CBZ was 
continued at the same or higher dose, and the tics abated 
and then ceased spontaneously s 6  months. In the third 
child, the tics ceased after CBZ discontinuation. These 
cases demonstrate that CBZ can induce simple motor tics 
in children. These idiosyncratic reactions may be tran- 
sient and do not always necessitate drug discontinuation. 
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A variety of drug-induced movement disorders 
have been described in association with antiepilep- 
tic drug (AED) therapy, most often with phenytoin 
(PHT), (Chadwick et al., 1976). Carbamazepine 
(CBZ) has been implicated as a possible or probable 
causative factor of various involuntary movements 
in 26 patients, half of whom were children (Berchou 
and Rodin, 1979; Crosley and Swender, 1979; Lehr- 
man and Bauman, 1981; Bradbury et al., 1982; Neg- 
lia et al., 1984; Weaver et al., 1988; Kurlan et al., 
1989; Schwartzmann and Leppik, 1990). The dyski- 
nesias in some patients appeared to represent toxic 
side effects of high CBZ concentrations, whereas in 
others the involuntary movements appeared to be 
idiosyncratic reactions, occurring in patients with 
therapeutic blood levels. Most previously described 
CBZ-associated involuntary movements in children 
were generalized dyskinesias associated with dys- 
tonic or choreoathetotic movements in axial or ex- 
tremity musculature. Development of motor tics in 
association with CBZ therapy is uncommon and has 
been reported in only 4 children; in all, CBZ ap- 
peared to have precipitated or exacerbated an un- 
derlying Tourette’s syndrome (Neglia et al., 1984; 
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Kurlan et al., 1989). We report 3 children with no 
previous history of involuntary movements who de- 
veloped facial motor tics soon after CBZ initiation. 
CASE REPORTS 
Case 1 
A 5-year-boy with a history of developmental lan- 
guage delay and episodes of staring and unrespon- 
siveness had an unremarkable birth and past medi- 
cal history. Developmentally, fine and gross motor 
skills were normal. He was able to say single words 
by age 1 year, but expressive language progressed 
at a slower than normal rate thereafter. There was 
no family history of mental retardation, language 
disability, seizure, or tic disorder. Computed to- 
mography (CT) brain scan was normal. EEG 
showed frequent left frontocentral spike and slow 
waves, and the staring episodes were presumptively 
diagnosed as complex partial seizures. Therapy 
with CBZ was started at a dosage of 10 mg/kg/day. 
Within 2 weeks after initiation of CBZ, facial move- 
ments began, consisting of alternately wide opening 
and then tight closing of his eyes, along with fre- 
quent repetitive blinking and jaw clenching. These 
movements had never been observed before CBZ 
initiation. Although his family was concerned about 
the movements, he did not appear to be distressed 
by them. CBZ blood level at that time was 4.1 pg/ 
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ml, and an EEG showed no correlation of the move- 
ments with any epileptiform activity. The involun- 
tary movements were diagnosed as motor tics. Be- 
cause CBZ had abolished the staring spells and the 
child’s speech had become significantly more flu- 
ent, no CBZ dosage changes were made. Blinking 
and other facial movements decreased in the next 2 
months, although CBZ level remained unchanged. 
After 4 months of CBZ, the question of behavioral 
side effects was raised, and CBZ dosage was de- 
creased by 25%. The tics disappeared completely 
after another 2 more months, at which time the CBZ 
level was 3.6 pg/ml. The CBZ dosage was then re- 
stored to the original 10-mg/kg/day dosage with no 
recurrence of tics during 6 months of follow-up 
while receiving CBZ. 
Case 2 
A 17-year-old boy had a history of complex par- 
tial seizures (CPS) that began at age 2 with viral 
encephalitis. Seizures were controlled with pheno- 
barbital (PB) and PHT until age 12. AEDs were 
discontinued until age 15, when he again began to 
have seizures refractory initially to PB and acet- 
azolamide and then to valproate (VPA) and PHT. 
EEG showed seizure origin in left frontal regions. 
Past medical history included well-controlled 
asthma. Developmental history was normal, and he 
had been an A student in school until grades fell 
with seizure recurrence. There was no family his- 
tory of movement or tic disorder. Brain magnetic 
resonance imaging (MRI) showed no abnormalities. 
PHT was discontinued, and VPA was changed to 
CBZ 5 mg/kg/day. Repetitive eye blinking began 11 
days after CBZ initiation. CBZ blood level was 7.2 
pg/ml, and VPA blood level was 36 pg/ml. There 
were no other signs of clinical toxicity. Movements 
did not correlate with any abnormal EEG activity 
and were diagnosed as facial tics. He had experi- 
enced no previous involuntary movements. VPA 
was discontinued after 9 days with persistence of 
the blinking. CBZ dosage was increased to 6 mg/kg/ 
day. Tics began to abate and disappeared -2 
months after CBZ initiation when the blood level 
was 7.6 pg/ml, but recurred after a further increase 
in dosage to 8 mg/kg/day, when the level was 8.4 
pg/ml. The tics again resolved after another month 
and did not recur when the dosage was subse- 
quently increased to 19 mg/kg/day and CBZ levels 
were between 13 and 19 pg/ml. No tics were ob- 
served for the next 6 months while he continued 
CBZ. 
Case 3 
A 9-year-old boy had a history of several different 
types of occasional paroxysmal episodes since early 
infancy, including one with arm jerking and several 
with sudden loss of postural tone and alteration of 
consciousness. There was also a 2-year history of 
throbbing bifrontal headaches that had more re- 
cently become associated with visual image distor- 
tion and d6ja vu phenomena. Past medical history 
was unremarkable. Developmental milestones had 
been normal, and he was an honor student in 
school. Family history was unknown because he 
was adopted. A diagnosis of migraine headache was 
considered, but an EEG showed left frontotemporal 
spikes and polyspikes consistent with the interictal 
expression of a complex partial seizure disorder. 
CBZ was initiated at a dosage of 5 mg/kg. Brain 
MRI showed no abnormalities. Headaches im- 
proved initially, but 6 weeks after CBZ initiation 
repetitive facial movements with mouth opening 
and tongue curling began. These had never been 
observed before CBZ. Movements were diagnosed 
as facial motor tics. CBZ blood level was 3.2 pg/ml, 
and CBZ dosage was not altered. The tics gradually 
lessened, but because the headaches and visual 
symptoms became worse, the CBZ dosage was in- 
creased to 7.5 mg/kg/day 4 months after CBZ initi- 
ation. Tics became more prominent during the next 
2 months. CBZ blood level was only 1.5 pg/ml, but 
several doses had been missed on the day before the 
blood level was obtained. Because the headaches 
persisted, primidone (PRM) was initiated, and CBZ 
tapered and discontinued; subsequently, the tics 
ceased completely. 
DISCUSSION 
Three children developed facial motor tics mani- 
fest as repetitive blinking, jaw opening or clenching, 
and tongue movements 2-6 weeks after initiation of 
CBZ therapy. Two received no other drugs. The 
third (case 2), in whom VPA was being discontin- 
ued, received VPA for 9 days after tic onset; the tics 
then continued for several months. The temporal 
association of CBZ initiation with tic onset, along 
with the absence of other likely etiologic factors, 
suggests that CBZ was the most likely cause. 
Tics have been reported in association with CBZ 
therapy in only 4 other pediatric patients, 3 of 
whom had already manifested motor tics that wors- 
ened after CBZ initiation (Neglia et al., 1984; Kur- 
lan et al., 1989). Two adults, one with Huntington’s 
disease and the other with Alzheimer’s disease, also 
developed tics superimposed on other types of in- 
voluntary movements after introduction of CBZ 
(Kurlan et al., 1989). In the 4 reported children, the 
CBZ-induced tics persisted even after CBZ discon- 
tinuation, were multifocal, included phonic tics, 
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and in 3 required haloperidol for control, suggesting 
that these children had Tourette’s syndrome that 
was unmasked or exacerbated by the CBZ, as oc- 
curs with stimulant medications such as amphet- 
amine (Lowe et al., 1982). 
CBZ blood levels of our patients, as of those pre- 
viously reported with CBZ-associated tics, were in 
the therapeutic range, suggesting the reaction is id- 
iosyncratic rather than a toxic effect of excessively 
high CBZ concentrations. Unlike the previous 
cases, however, our children did not exhibit tics 
before initiation of CBZ therapy and did not prog- 
ress to Tourette’s syndrome. Moreover, in cases 1 
and 2, tic manifestations were transient. Even 
though CBZ was continued at the same or higher 
dosage, the tics abated and finally ceased within 
several months. In case 3,  the tics resolved after 
CBZ discontinuation. 
CBZ has also been reported as a probable cause 
of other involuntary movements in both adults and 
children (Berchou and Rodin, 1979; Crosley and 
Swender, 1979; Lehrman and Bauman, 1981; Brad- 
bury et al., 1982; Critchley and Phillips, 1988; 
Weaver et al., 1988; Schwartzmann and Leppik, 
1990). Eight children were described with general- 
ized dyskinesias; 7 of these had movements that 
involved axial and/or extremity muscles in dys- 
tonic, choreoathetotic, or even ballistic patterns 
(Crosley and Swender, 1979; Lehrman and Bau- 
man, 1981; Bradbury et al., 1982; Critchley and 
Phillips, 1988; Weaver et al., 1988), and I child de- 
veloped shivering movements with rigidity and hy- 
pokinesia (Critchley and Phillips, 1988). In 4 of the 
8 children, CBZ levels were clearly above therapeu- 
tic range (>20 pg/ml) and the CBZ had been in- 
gested either accidently or deliberately as an over- 
dose in 3; all 4 also had alterations in level of con- 
sciousness. (Lehrman and Bauman, 1981 ; Bradbury 
et al., 1982; Weaver et al., 1988). In contrast, the 
remaining 4 children with generalized dyskinesias 
(Crosley and Swender, 1979; Critchley and Phillips, 
1988), and 1 other child who developed forced up- 
ward eye deviation in oculogyric crisis (Berchou 
and Rodin, 1979), had CBZ levels that either were 
in the therapeutic range or were not measured. 
Overdose was not suspected, and no other clinical 
sign of intoxication accompanied the movements, 
suggesting that, like the tics we observed, they were 
idiosyncratic rather than toxic CBZ reactions. 
Some of the reported patients who developed ab- 
normal movements during CBZ treatment had sig- 
nificant underlying brain damage and neurologic im- 
pairment, and disruption of the integrity of the basal 
ganglia has been suggested to be a predisposing fac- 
tor for CBZ-induced movement disorders (Crosley 
and Swender, 1979). The possibility of some subtle 
underlying neurologic abnormalities cannot be 
ruled out in our patients, particularly in case 1 who 
did have neurodevelopmental abnormalities of 
speech. Yet these case histories demonstrate that 
tics can occur when brain imaging shows no struc- 
tural abnormalities and, in cases 2 and 3,  when neu- 
rologic examination shows no abnormality. 
CBZ at therapeutic levels can induce tics in chil- 
dren who have no underlying movement disorder or 
major neurologic deficit. The relatively mild and 
transient nature of CBZ-induced involuntary move- 
ments, even when CBZ is continued, suggests that 
if clinically warranted, it may be feasible to con- 
tinue CBZ treatment. 
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F&SUME 
DiffCrents types de mouvements anormaux peuvent &tre liCs a 
la prescription de carbamazkpine (CBZ) chez I’adulte et chez 
I’enfant, mais le dCveloppement de tics n’a Ctt dCcrit que 
rarement, seulement chez les patients prCsentant une maladie de 
Gilles de la Tourette sous-jacente ou d’autres mouvements an- 
ormaux. Les auteurs prtsentent 3 observations d’enfants Cpilep- 
tiques qui ont dtveloppC des tics moteurs faciaux aprts mise en 
route de CBZ en traitement de crises partielles complexes. Chez 
les 3 patients, les taux sanguins de CBZ Ctaient dans les zones 
thkrapeutiques pendant cette pCriode, et aucun n’avait d’autres 
symptbmes ou signes d’intoxication clinique. L’examen neu- 
rologique Ctait normal chez 2 patients, le troisieme prCsentant un 
retard d’expression du langage. La neuroradiologie ctrCbrale 
Ctait normale chez les 3 patients. Aprhs l’installation des tics, le 
traitement par CBZ a 6tC poursuivi chez 2 patients a la m&me 
dose ou a une dose supkrieure, et les tics ont diminuC et ont 
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disparu spontankment en moins de 6 mois. Chez le 3eme enfant, 
les tics se sont arr&tks apres arrCt de la CBZ. Ces cas montrent 
que la CBZ peut induire des tics moteurs simples chez l’enfant. 
Ces rbactions idiosyncrasiques peuvent &re transitoires et na 
nkcessitent pas toujours l’arret du medicament. 
(P. Genton, Marseilie) 
RESUMEN 
Aunque se conocen varios trastornos de movimiento durante 
el tratamiento con carbamazepina (CBZ) en adultos y en nidos, 
el desarrollo de tics ha sido infrecuentemente descrito y s61a- 
mente en pacientes que tenian un sindrome de Tourette u otros 
trastornos del movimiento. Los autores presentan 3 nidos con 
epilepsia que desarrollaron tics motores faciales trans la inicia- 
ci6n de un tratamiento con CBZ por padecer crisis parciales 
complejas. Los 3 enfermos tenian niveles terapkuticos sanguin- 
eos de CBZ y ninguno mostro signos o slntomas de intoxicacion. 
La exploracih neurologica fue normal en 2 y el tercero mostr6 
una lentificacion en el desarrollo del lenguahe expresivo. Los 
estudios de imagen cerebral fueon normales en 10s 3 casos. Tras 
el desarrollo de 10s tics, en 2 casos la CBZ se mantuvo en las 
mismas o en dosis mas elevadas y 10s tics se redujeron. Poste- 
riormente, se interrumpieron espontaneamente en un period0 de 
6 meses. En el tercer nifio 10s tics se interrumpieron desputs de 
la interruption de la CBZ. Estos casos demuestran que la CBZ 
puede inducir tics simples motores en niiios. Esta reacci6n idi- 
osicrasica puede ser transitoria y no se siempre necesita la in- 
terrupcion de la medicacion. 
(A. Portera-Sanchez, Mudrid) 
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